Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5949584 | 1.00 | ALOX5 (0.53) | ALOX5MTORCYP2D6TRPM8KMT2A | |
| SCHEMBL6174375 | 0.80 | CYP3A4 (0.42) | ALOX5KMT2AALDH1A1 | |
| SCHEMBL2842918 | 0.78 | CYP2D6 (0.44) | ALOX5CYP2D6KMT2AKDM4EALDH1A1 | |
| SCHEMBL10012935 | 0.78 | ALOX5 (0.47) | ALOX5MTORCYP2D6TRPM8KMT2A | |
| SCHEMBL6222175 | 0.78 | SMN1; SMN2 (0.43) | KDM4EALDH1A1 | |
| SCHEMBL4310309 | 0.77 | ALDH1A1 (0.47) | ALOX5MTORCYP2D6TRPM8KMT2A | |
| SCHEMBL31061559 | 0.77 | ALDH1A1 (0.47) | ALOX5MTORCYP2D6TRPM8KMT2A | |
| SCHEMBL14394131 | 0.75 | ALOX5 (0.48) | ALOX5MTORTRPM8KDM4E | |
| SCHEMBL11215910 | 0.75 | ALOX5 (0.57) | ALOX5MTORKMT2AKDM4EALDH1A1 | |
| SCHEMBL6176307 | 0.75 | MMP2 (0.46) | ALOX5CYP2D6TRPM8KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6350902-B2 | REACTING HYDROXYAMINE WITH A TRIFLUOROFORMATE ESTER | ABBOTT LABORATORIES | 2002-02-26 | — | — | US | disclosed |
| US-20020002307-A1 | Process for the selective N-formylation of N-hydroxylamines | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| US-20010031896-A1 | Process for the selective N-formylation of N-hydroxylamines | ABBOTT LABORATORIES | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031896-A1 | Process for the selective N-formylation of N-hydroxylamines | HNMT, INMT, PNMT | ALOX5 1066/4885MTOR 4505/4885CYP2D6 870/4885 |
| US-20020002307-A1 | Process for the selective N-formylation of N-hydroxylamines | HNMT, INMT, PNMT | ALOX5 1066/4885MTOR 4505/4885CYP2D6 870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.